Last updated 5 months ago
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)
3980 patients around the world
Available in Argentina
Chiesi Farmaceutici S.p.A.
1Research sites
3980Patients around the world
Requirements for the patient
From 40 Years
All Gender
Medical requirements
Sites
Monseñor Pablo Cabrera 2941, Córdobawww.cemaic.com.ar
StudyPILLAR
SponsorChiesi Farmaceutici S.p.A.
Requirements
From 40 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT04636814
